Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some safety setbacks and years of generic competition, Takeda is calling it quits ...

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

Takeda has ended the manufacturing and supply of its gout drug Uloric in the US market as more patients turn to generic ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...

Drug companies, like Takeda, the maker of Vyvanse, have until 2028. Red No. 3 is present in about a quarter of baking ...

The global antibody drug conjugates market size was valued at USD 11.84 billion in 2024 and is projected to reach from USD 12.89 billion in 2025 to USD 25.38 billion by 2033, growing at a CAGR of 8.84 ...